The U.S. Food and Drug Administration confirmed a shortage of the medication commonly referred to by the brand name Adderall.
“FDA is in frequent communication with all manufacturers of amphetamine mixed salts, and one of those companies, Teva, is experiencing ongoing intermittent manufacturing delays,” the FDA said in a statement on Wednesday. “Other manufacturers continue to produce amphetamine mixed salts, but there is not sufficient supply to continue to meet U.S. market demand through those producers.”
Teva Pharmaceutical Industries Ltd. in a statement to USA TODAY said it has “active supply of both branded Adderall and its generic version and continues to produce and refill the channel regularly at levels above historical demand.”
“It is possible that some people may encounter a backorder (intermittently) based on timing and demand, but these are only temporary,” the company added in an emailed statement, adding that it expects “inventory recovery in the coming months.”